Annual report pursuant to Section 13 and 15(d)

License Agreements (Details)

v3.22.1
License Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2015
May 11, 2015
Jun. 30, 2019
May 31, 2016
Mar. 31, 2015
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2016
Neupharma                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of upfront licensing fees         $ 1,000,000.0      
Neupharma | Additional Sales Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           $ 40,000,000.0    
Neupharma | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           40,000,000.0    
Neupharma | Regulatory Approvals To Commercialize The Products                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           22,500,000    
Dana-Farber                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Number of shares of common stock granted 136,830 500,000            
Payment of upfront licensing fees         1,000,000.0      
Ownership percentage   5.00%            
Cash in exchange for common shares   $ 10,000,000            
Maintenance fee           50,000    
Non-Refundable Milestone Payment           4,000,000.0 $ 925,000  
Value of common stock shares issued $ 600,000 $ 32,500            
Sale price per share   $ 0.065            
Dana-Farber | First Commercial Sale Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           21,500,000    
Dana-Farber | Additional Sales Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           60,000,000.0    
Maximum potential milestone payments           60,000,000.0    
Jubilant Biosys Ltd                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of upfront licensing fees               $ 2,000,000.0
Revenue recognition milestone revenue recognized           $ 100,000 100,000  
Proceeds from upfront fees       $ 1,000,000.0        
Research and development cost           50.00%    
Jubilant Biosys Ltd | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           $ 89,000,000.0    
Jubilant Biosys Ltd | Regulatory Approvals To Commercialize The Products                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           59,500,000    
Jubilant Biosys Ltd | Five Regulatory Approvals And First Commercial Sales                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           61,700,000    
Jubilant Biosys Ltd | Sale Millstone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           89,000,000.0    
Maximum potential milestone payments           89,000,000.0    
Jubilant Biosys Ltd | Clinical Development and Regulatory Milestones                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           87,200,000    
Adimab LLC                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Non-Refundable Milestone Payment           2,400,000    
Adimab LLC | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           7,100,000    
Adimab LLC | Regulatory Approvals To Commercialize The Products                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           4,800,000    
Collaboration Agreement With TGTX                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone revenue recognized           200,000 $ 1,000,000.0  
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000      
Collaboration Agreement With TGTX | First Commercial Sale Milestone | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           27,600,000    
Collaboration Agreement With TGTX | First Commercial Sale Milestone | PD-L1 GITR                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           14,500,000    
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           8,400,000    
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1 GITR                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           7,000,000.0    
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           19,200,000    
Sublicense Agreement with TGTX | Clinical and Development Milestone                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           25,500,000    
Collaboration Agreement With GITR | PD-L1 GITR                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           $ 21,500,000